BC
INZY

BIT Capital’s Inozyme Pharma INZY Stock Holding History

BIT Capital’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-63,799
Closed -$177K – 131
2024
Q4 		$177K Buy
+63,799
New +$243K 0.01% 100
2024
Q1 		– Sell
-37,837
Closed -$161K – 122
2023
Q4 		$161K Buy
37,837
+8,708
+30% +$30.9K 0.02% 77
2023
Q3 		$122K Hold
29,129
– – 0.01% 95
2023
Q2 		$162K Sell
29,129
-25,097
-46% -$148K 0.02% 118
2023
Q1 		$311K Buy
+54,226
New +$143K 0.05% 100

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT Capital's INZY Position: Q1 2025 in Review

BIT Capital sold out of Inozyme Pharma (INZY) in Q1 2025, closing a stake of 63,799 shares — an estimated $177K sold.

BIT Capital first reported a position in INZY in Q1 2023 and held it in 5 quarters. The position peaked at $311K in Q1 2023. 97 funds tracked by Wall St. Rank hold INZY as of Q1 2025.

  • BIT Capital reported no remaining Inozyme Pharma position as of Q1 2025 after selling out during the quarter.
  • BIT Capital sold 63,799 Inozyme Pharma shares in Q1 2025, an estimated $177K.
  • BIT Capital first reported a position in Inozyme Pharma in Q1 2023 and held it in 5 quarters.
  • BIT Capital's Inozyme Pharma position peaked at $311K in Q1 2023.
  • 97 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2025.

Based on BIT Capital's 13F filing for Q1 2025, filed 9 May 2025.